Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633033 · ClinicalTrials.gov registry record
Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse
A clinical trial of Multiple Sclerosis (Relapsing Remitting), sponsored by Mallinckrodt.
- Completed
- Registry status
- 160
- Enrollment target
- 20
- Study locations
NCT02633033: Completed study of Multiple Sclerosis (Relapsing Remitting), sponsored by Mallinckrodt.
NCT02633033 is a study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Mallinckrodt. The registered enrollment target is 160 participants, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02633033, a study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
Acthar Gel was first approved by the Food and Drug Administration in 1952. It has been used to treat many different illnesses, including multiple sclerosis. This study will observe how treatment with Acthar affected the daily lives of patients who suffer with relapsing/remitting MS. It will collect information on symptoms, recovery, treatment patterns and safety outcomes.
Primary Outcome
Participants rate 20 physical symptoms of multiple sclerosis (MS) on a scale from 1=not at all to 5=extremely. The highest possible score is 100. Higher scores mean physical symptoms of MS have a higher impact on day-to-day life. For patients having a relapse during the study period, the schedule of assessments restarts at the time of relapse(s).
Conditions Studied
Study Locations (20)
Florida
- Emery Neuroscience Center - Lighthouse PT
- Neurology Associates - Maitland
- Cordova Research Institute - Miami
- Collier Neurologic Specialists - Naples
- Florida Neurological Center - Ocala
- Neurological Services of Orlando - Orlando
- Neurology Associates of Ormond Beach - Ormond Beach
- Negroski, Sutherland and Hanes Neurology - Sarasota
- Infinity Clinical Research - Sunrise
Georgia
- Columbus Research & Wellness Institute - Columbus
- Neurology of Central Georgia - Macon
- Meridian Clinical Research - Savannah
Colorado
- Colorado Springs Neurological Associates - Colorado Springs
- Advanced Neurosciences Research - Fort Collins
Alabama
- Alabama Neurology Associates - Homewood
Arizona
- Territory Neurology & Research Institute - Tucson
Connecticut
- Associated Neurologists of Southern Connecticut - Fairfield
District of Columbia
- MedStar Health - Washington D.C.
Kansas
- College Park Family Care Center - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2015-11-24 |
| Est. Completion | 2019-05-09 |
What the finished NCT02633033 record still lists
NCT02633033 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 0 interventions.
NCT02633033 names 20 study sites across 9 states, led by Florida, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT02633033 about?
NCT02633033 is a clinical study titled "Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse". Acthar Gel was first approved by the Food and Drug Administration in 1952. It has been used to treat many different illnesses, including multiple sclerosis. This study will observe how treatment with Acthar affected the daily lives of patients who suffer with relapsing/remitting MS. It will colle...
What is the current status of trial NCT02633033?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2015-11-24. Estimated completion is 2019-05-09.
What conditions does trial NCT02633033 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
Who is sponsoring clinical trial NCT02633033?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02633033 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02633033's enrollment target sits among peer trials
160 11th of 29 higher than 19 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
MS-ResearchBiomarkerS
RECRUITING
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI